Apollo Therapeutics
Biotechnology Research • 
United Kingdom • 51-100 Employees
Company overview
| Headquarters | United Kingdom |
| Websites | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Biotechnology, Oncology, Biopharmaceuticals, Therapeutics, Rare Disease, Major Inflammatory Disorders |
| Employees | 51-100 |
| Socials |
Key Contacts at Apollo Therapeutics
Joshua Black
Sr. Director Clinical Operations
Neil Flanagan
Director Of Cmc
Nicole Cipriano
Associate Director
Robert Shine
Director, Development Project Manager
Ian Nicoll
Director, Us Financial Reporting
Brittany Bahamon
Director, Program Manager
Bonnie Petka
Director, Development Project Manager
Laurie Green
Director Clinical Operations
Pegah Saremirad
Associate Director Cmc
Nathan Hubbard
Fp&A Director
Apollo Therapeutics Email Formats
Apollo Therapeutics uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@apollotherapeutics.com), used 86.4% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@apollotherapeutics.com | 86.4% |
{first name}.{last name} | john.doe@apollotherapeutics.com | 13.6% |
About Apollo Therapeutics
Apollo Therapeutics is a biopharmaceutical company rapidly advancing a robust pipeline of potentially transformative therapeutic programs based on breakthrough discoveries. Through deep relationships with world-leading universities and scientists, the company identifies programs with strong biological hypotheses and potential to become meaningful new treatment options. Apollo’s portfolio-based model combines a centralized team of drug development ‘architects’ and subject matter experts who are able to rigorously evaluate therapeutic programs in an objective, data-driven manner – prioritizing critical experiments to de-risk programs early. This capital efficiency allows Apollo to focus on scaling a robust and potentially transformative pipeline, with over 15 therapeutic programs in development today across oncology, major inflammatory disorders and rare disease. Apollo’s innovative model was created in late 2015 by three world-leading universities Cambridge, Imperial College London and University College London in partnership with AstraZeneca, GlaxoSmithKline and Johnson & Johnson Innovation. There is significant opportunity ahead of us to bring new treatments to market as our lead programs move into clinical development. We will look to build on our existing collaborations, foster new relationships with additional top academics around the world and in-license drug candidates from new partners. Apollo is funded by Patient Square Capital, Rock Springs Capital, Reimagined Ventures and UCL Technology Fund. We are expanding our operations in Cambridge, UK and Boston, USA. For more information, please visit our website at www.apollotherapeutics.com
Apollo Therapeutics revenue & valuation
| Annual revenue | $3,000,000 |
| Revenue per employee | $50,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $9,600,000 |
| Total funding | $258,500,000 |
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Apollo Therapeutics has 31 employees across 8 departments.
Departments
Number of employees
Funding Data
Explore Apollo Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
Apollo Therapeutics Tech Stack
Discover the technologies and tools that power Apollo Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Security
JavaScript libraries
Analytics
CDN
Web servers
JavaScript libraries
Programming languages
Security
Blogs
Analytics
SEO
Australia
Israel
Frequently asked questions
4.8
40,000 users
